UK regulatory approval for SCIB1 phase II advanced melanoma trial
The study is designed to assess whether the addition of SCIB1 treatment will result in an improvement in the tumour response rate.
Read More
Tag: SCIB1
- CERo reports encouraging early data from phase 1 trial of CER‑1236
- ENA Respiratory begins dosing in phase 2 study of INNA‑051 nasal spray
- Argo Biopharma doses first patient in phase 2b trial of BW‑20829
- Akari files new patent and advances second ADC targeting CEACAM5
- BioMed X launches kidney disease project in partnership with the government of Barbados
